A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
Recruiting · Phase 1 · NCT06801223
Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
At a glance
- Research payments reported, 2025
- $103,398
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- Innoviva Specialty Therapeutics (with Entasis Therapeutics)
- Tested
- Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours) (drug), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours) (drug), Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours) (drug), Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours) (drug)
- Dates
- Started 2026-12-30; completion 2028-05-20
- Results posted
- Not yet
The goal of this clinical trial is to investigate the use of Sulbactam-Durlobactam (SUL-DUR) in pediatric patients and is being conducted to collect pharmacokinetic (PK) and safety data to enable the identification of appropriate pediatric dosing regimens for patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections
From ClinicalTrials.gov, last updated 2026-10-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $103,398 in research payments for this study in 2025 (11 payments).
Products named: Xacduro
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John S. Bradley, M.D. Pediatric Infectious Disease · San Diego, CA
- Jaime G. Deville, M.D. Pediatric Infectious Disease · Los Angeles, CA
- Lemuel O. Aigbivbalu, M.D. Pediatrics · Galveston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.